DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
Sorensen B, Mant T, Georgiev P , et al; on behalf of ALN-AT3 Investigators.
A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in patients with hemophilia A or B.
J Thromb Haemost 2015;
13 (Suppl. 02) OR213 (abstract)
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.